Kura Oncology (KURA) Non-Current Debt (2014 - 2026)

Kura Oncology (KURA) has 12 years of Non-Current Debt data on file, last reported at $9.7 million in Q1 2026.

• Quarterly Non-Current Debt rose 27.44% year-over-year to $9.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (up 27.44% YoY) and the FY2025 annual result came in at $9.7 million, up 40.41% from the prior year.
• Non-Current Debt steadied at $9.7 million in Q1 2026 per KURA's latest filing, from $9.7 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $9.7 million in Q1 2026 and bottomed at $5.3 million in Q3 2025.
• The 5-year median for Non-Current Debt is $9.2 million (2022), against an average of $8.4 million.
• Peak annual rise in Non-Current Debt reached 40.41% in 2025, while the deepest fall reached 31.21% in 2025.
• Tracing KURA's Non-Current Debt over 5 years: stood at $9.2 million in 2022, then grew by 1.9% to $9.3 million in 2023, then dropped by 25.89% to $6.9 million in 2024, then surged by 40.41% to $9.7 million in 2025, then grew by 0.39% to $9.7 million in 2026.
• Per Business Quant, the three latest KURA Non-Current Debt figures stand at $9.7 million (Q1 2026), $9.7 million (Q4 2025), and $5.3 million (Q3 2025).

Peer Comparison